Clinical Research Directory

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer

Sponsor: AbbVie

Summary

Small cell lung cancer (SCLC) is a type of lung cancer that accounts for approximately 15-17% of all lung cancers. It is characterized by aggressive and rapid growth and early spread to distant sites. Extensive stage-small cell lung cancer (ES-SCLC) includes cases where disease has spread beyond one side of the chest. The purpose of this study is to assess safety and efficacy of ABBV-706 in combination with tarlatamab and atezolizumab in participants with ES-SCLC. ABBV-706 is an investigational drug being developed for the treatment of ESSCLC. This is an open-label study, meaning participants and doctors know which treatment is being given. Participants are placed into 1 of 2 treatment arms. Each arm receives a different dose of ABBV-706 in combination with tarlatamab and atezolizumab. Adult participants with a diagnosis of extensive stage-small cell lung cancer will be enrolled. Around 80 participants will be enrolled in the study at approximately 25 sites worldwide. Participants will receive intravenous (IV) doses of ABBV-706 in combination with IV atezolizumab and IV tarlatamab. The study will run for a duration of approximately 62 months. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, imaging scans, checking for side effects and completing questionnaires.

Official title: A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of ABBV-706 in Combination With Tarlatamab and Atezolizumab in First-Line Extensive Stage-Small Cell Lung Cancer (ES-SCLC)

Key Details

Conditions

Interventions